Royalty Pharma PLC
(FRA:RPD)
€
48.55
-0.53 (-1.08%)
Market Cap: 43.15 Bil
Enterprise Value: 51.99 Bil
PE Ratio: 32.07
PB Ratio: 3.67
GF Score: 72/100 
Q2 2026 Royalty Pharma PLC Earnings Call Transcript
Aug 05, 2026 / 12:00PM GMT
Release Date Price:
€49.51
(+2.55%)
Key Points
Positve
- Royalty Pharma PLC (RPRX) delivered strong financial performance in Q2 2026, with portfolio receipts growing 6% and total receipts up 14%, exceeding guidance and marking the 25th consecutive quarter of double-digit growth.
- The company raised its full-year 2026 guidance for the second consecutive quarter, now expecting portfolio receipts of $3.4 billion to $3.5 billion and royalty receipts growth of 7% to 10%.
- Royalty Pharma PLC (RPRX) continues to generate high returns, with return on invested capital of 14.2% and return on invested equity of 20.1% over the last 12 months.
- The acquisition of a 3.75% royalty on AstraZeneca's cliramitug, a potential blockbuster for ATTR-CM, adds a differentiated asset with peak annual royalty potential of $110 million to $190 million and an expected IRR in the teens.
- The development-stage pipeline has expanded significantly to 19 potential therapies, with peak royalty potential of approximately $2 billion and a 90% historical success rate in achieving regulatory approval.
- Royalty Pharma PLC (RPRX) achieved a credit rating upgrade to BBB from all major agencies, enhancing financial flexibility with access to over $4 billion in cash, revolver, and debt markets.
- The company returned approximately $367 million to shareholders in the first half of 2026 through dividends and share repurchases, demonstrating a commitment to capital returns.
- Portfolio diversification and strong performance from key assets like Tremfya, Voranigo, Emdeltra, and Evrysdi helped absorb headwinds from Promacta and IMBRUVICA, enabling double-digit royalty receipts growth.
- The company's unique business model and barriers to entry, including a $22 billion invested capital portfolio and irreplaceable royalties, provide a significant competitive moat.
- Royalty Pharma PLC (RPRX) is expanding into new growth areas, including synthetic royalties and the Chinese market, with a strong team and strategic hires to drive long-term opportunities.
Negative
- Milestones and other contractual receipts declined significantly in Q2 2026 due to a one-time payment in the prior year period, impacting overall portfolio receipts growth.
- The company faces headwinds from the loss of exclusivity for Promacta and the launch of biosimilar TYSABRI in the US, which could pressure future royalty receipts.
- The cliramitug royalty is dependent on the success of a Phase III outcomes trial, with results not expected until 2028, introducing clinical and regulatory risk.
- The development-stage pipeline, while promising, carries inherent risks, and the company's guidance does not account for potential future royalty acquisitions, limiting upside visibility.
- Operating costs are expected to increase in the second half of 2026 due to seasonality, potentially impacting margins despite the benefits of internalization.
- The company's leverage stands at 2.8 times total debt to adjusted EBITDA, and interest payments are expected to be around $350 million to $360 million in 2026, which could constrain capital deployment.
- The synthetic royalty opportunity, while growing, remains a small portion of the overall biopharma funding market, and scaling it may face challenges in deal flow and competition.
- Expansion into the Chinese market is still in early stages, with regulatory and policy risks, including potential US restrictions on investments, posing uncertainties.
- The company's reliance on a few key products for growth, such as Tremfya and Evrysdi, exposes it to concentration risk if these assets underperform.
- The potential impact of the cardio transform trial on the TTR market, while possibly benefiting Amvuttra, introduces uncertainty in the competitive landscape for cliramitug.
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma's second quarter 2026 earnings conference call. I would like now to turn the conference over to George Grofik, Senior Vice President Head of Investor Relations and Communications. Please go ahead, sir.
George Grofik Royalty Pharma PLC;Senior Vice President Head of Investor Relations and Communications
Good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's second quarter results. You can find the press release with our earnings results and slides of this call on the Investors page of our website at royaltypharma.com.
On Slide 2, I'd like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from these statements. We refer you to our most recent 10-K on file with the SEC for a description of these risks. All forward-looking statements are based on information
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers